Skip to content

Study of the PAS-Port® Proximal Anastomosis System in Coronary Bypass Surgery

Use of the PAS-Port Proximal Anastomosis System for Creation of Aorto-Venous Proximal Anastomoses in Coronary Bypass Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00355563
Acronym
EPIC
Enrollment
220
Registered
2006-07-24
Start date
2006-06-30
Completion date
2008-04-30
Last updated
2009-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Brief summary

The study has been designed to comparatively evaluate the safety and effectiveness of the PAS-Port Proximal Anastomosis System and conventional suturing techniques for creation of the connection between graft veins and the aorta in patients undergoing coronary artery bypass graft surgery for treatment of coronary artery disease. Patients in the study will have a coronary angiogram approximately 9 months following surgery to determine the patency of vein grafts created using either the automated PAS-Port or hand sewn methods. Safety will be evaluated by documenting the occurence of adverse clinical events and evealuating possible association with either method.

Interventions

DEVICEPAS-Port Automated Proximal Anastomosis System

Sponsors

Cardica, Inc
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

PRE-OPERATIVELY Inclusion Criteria: * Able to give informed consent, able to understand the intent and clinical meaning of the study as well as its implications. Patient is legally competent. * Assessment that the patient is willing and able to have follow-up visits and examinations * Age greater than or equal to 50 years and less than 85 years * Ejection fraction of \>30% * Can tolerate radiographic contrast media * Requires non-emergent coronary artery bypass with at least two vein bypass grafts intended * Coronary artery targets intended for bypass index grafts must have \>70% native stenosis * Life expectancy \>1 year

Exclusion criteria

* Patient is participating in other clinical trials that would conflict with this protocol * Unable to meet study requirements (travel, general health) * Pregnancy * Previous cardiac surgery * Requiring preoperative use of an intraaortic balloon pump * Congestive heart failure / NYHA Class IV * History of thromboembolic disease requiring ongoing anticoagulation therapy or the presence of a bleeding disorder * Acute or chronic dialysis * Creatinine of greater than 200 µmol/L (2.3 mg/dL) in the last 30 days * Documented acute or suspected systemic infection * Need for ongoing immunosuppressive therapy * Recent (less than 2 weeks) history of cerebrovascular accident * Aspirin allergy or other contraindications to aspirin use INTRA-OPERATIVELY Inclusion Criteria: * Patient is hemodynamically stable * Open chest reassessment of the revascularization strategy confirms that two vein bypass grafts are still intended * Target vessel wall properties that are suitable for performing both a hand-sewn and a PAS-Port anastomosis * Target vessel is greater than 1.8 mm in diameter at sites where anastomoses are planned * Target vessel at sites where anastomoses will be placed are free from severe calcifications or severe atheromas * The length of the vein graft(s) is adequate for both of the planned index graft revascularization strategies * Vein outside diameter and double wall thickness are between 4 and 6 mm(inclusive) and less than or equal to 1.4 mm, respectively, at the graft site intended for the PAS-Port proximal anastomosis * The vein(s) is of suitable quality to be used as a bypass graft conduit

Design outcomes

Primary

MeasureTime frame
Effectiveness: Graft Patency at 9 months post-operatively
Safety: Peri-and Post-operative MACE and SAE

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026